Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602070 | 0.81 | KDM5A (0.57) | KDM4EKMT2AMEN1RXFP1SMN1; SMN2 | |
| SCHEMBL3986764 | 0.81 | MEN1 (0.47) | KDM4EKMT2AMEN1SMN1; SMN2NLRP3 | |
| SCHEMBL4703123 | 0.77 | KDM5A (0.60) | KDM4EKMT2AMEN1KDM5AALDH1A1 | |
| SCHEMBL13631827 | 0.76 | PADI4 (0.35) | KDM4EKMT2AMEN1RXFP1ALDH1A1 | |
| SCHEMBL3985154 | 0.74 | KDM4E (0.74) | KDM4ETDP1KMT2AMEN1RXFP1 | |
| SCHEMBL3988851 | 0.73 | ACHE (0.53) | KDM4EKMT2AMEN1RXFP1SMN1; SMN2 | |
| SCHEMBL4698095 | 0.73 | NPC1 (0.68) | KDM4EKMT2AMEN1RXFP1SMN1; SMN2 | |
| SCHEMBL11090367 | 0.72 | GPR35 (0.39) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL1036962 | 0.72 | MAPT (0.67) | KDM4E | |
| SCHEMBL13597861 | 0.72 | SERPINE1 (0.53) | KMT2AMEN1RXFP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
| EP-2059305-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | Novartis Ag (CH) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008014307-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KDM4E 3718/4885TDP1 1147/4885KMT2A 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.